Rivus Pharmaceuticals’ MASH candidate reduced liver fat levels by up to 31.2% at six months in a Phase 2 trial in 221 overweight and obese MASH patients.
Dosed at 150 mg, 300 mg and 450 …
Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for
Plus, news about Codexis, Gilead, nChroma Bio, Bavarian Nordic, UroGen, Agenus, Accipiter Biosciences and Immunocore: ✂️ Sana trims cell therapy pipeline: The Seattle-based biotech is
ATLANTA — At one of the main annual gatherings of researchers and drug developers in the obesity field, Novo Nordisk and Eli Lilly were the
Eli Lilly is shaking up its neuroscience and immunology leadership, while giving two longtime executives additional responsibilities. The Indiana-based company said Thursday it has hired
Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.
Rivus Pharmaceuticals’ MASH candidate reduced liver fat levels by up to 31.2% at six months in a Phase 2 trial in 221 overweight and obese MASH patients.
Dosed at 150 mg, 300 mg and 450 …